Selective T-Cell Modulation for Autoimmune Disease Treatment

The patent applies local quality by transitioning from non-selective systemic immune suppression to selective modulation of specific T-cell populations. The method identifies and targets regulatory T-cells (Tregs) that specifically suppress autoimmune responses against self-tissues while preserving healthy responses to pathogens. This is achieved through in vitro identification of compounds that selectively induce immune tolerance to self-antigens, thereby providing localized immunological control rather than broad suppression.

The patent employs an intermediary approach by introducing specific compounds as mediators that facilitate selective immune tolerance. These compounds serve as intermediaries between the immune system and self-antigens, enabling the induction of regulatory T-cells that provide targeted suppression of autoimmune responses without compromising overall immune function. The compounds act as selective modulators that bridge the gap between autoimmunity and infection defense.

The patent applies parameter changes by optimizing the in vitro conditions for regulatory T-cell induction. The method systematically varies parameters such as compound concentration, exposure duration, and cellular environment to maximize the generation of functional regulatory cells. By identifying specific compounds and their optimal dosing regimens, the method transforms the qualitative induction process into a quantifiable and controllable parameter optimization, thereby achieving adequate numbers of functional Tregs.

The patent employs a copying strategy by creating in vitro models that replicate and amplify the natural induction of regulatory T-cells. The method uses in vitro assays to copy the complex in vivo immune tolerance induction process under controlled conditions, allowing for the efficient production and expansion of regulatory cells before administration to patients. This copying approach enables the scaling up of functional regulatory cell numbers.

The patent applies segmentation by dividing the immune system's dual functions into separately manageable components. Instead of suppressing the entire immune system, the method selectively targets and modulates specific T-cell populations (regulatory T-cells) that are responsible for autoimmune responses. This segmentation allows for the independent optimization of autoimmunity suppression while preserving pathogen response capabilities, thereby maintaining overall immune system balance.

The patent inverts the conventional approach by instead of broadly suppressing immune function, it focuses on enhancing and optimizing the regulatory function of the immune system. The method identifies and amplifies the natural regulatory capacity through selective induction of Tregs, effectively using the immune system's own regulatory mechanisms to restore balance rather than externally imposing suppression.